Fulcrum Therapeutics (FULC) Gross Profit: 2020-2024
Historic Gross Profit for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to $80.0 million.
- Fulcrum Therapeutics' Gross Profit rose 8990.91% to $80.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $82.5 million, marking a year-over-year increase of 2611.47%. This contributed to the annual value of $80.0 million for FY2024, which is 2752.05% up from last year.
- According to the latest figures from Q2 2024, Fulcrum Therapeutics' Gross Profit is $80.0 million, which was up 9,084.85% from $871,000 recorded in Q4 2023.
- In the past 5 years, Fulcrum Therapeutics' Gross Profit registered a high of $80.0 million during Q2 2024, and its lowest value of $295,000 during Q1 2023.
- In the last 3 years, Fulcrum Therapeutics' Gross Profit had a median value of $880,000 in 2023 and averaged $9.9 million.
- Its Gross Profit has fluctuated over the past 5 years, first plummeted by 88.62% in 2023, then skyrocketed by 8,990.91% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Gross Profit (Quarterly) stood at $4.2 million in 2020, then rose by 19.72% to $5.1 million in 2021, then slumped by 86.46% to $685,000 in 2022, then rose by 27.15% to $871,000 in 2023, then skyrocketed by 8,990.91% to $80.0 million in 2024.
- Its Gross Profit was $80.0 million in Q2 2024, compared to $871,000 in Q4 2023 and $759,000 in Q3 2023.